Published in BMJ on July 07, 2001
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain (2012) 2.13
Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol (2011) 1.88
Adverse effects of medical cannabinoids: a systematic review. CMAJ (2008) 1.86
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ (2004) 1.84
A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain (2008) 1.82
Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc (2012) 1.79
Is there a role for marijuana in medical practice? Can Fam Physician (2006) 1.62
Cannabis control: costs outweigh the benefits. For. BMJ (2002) 1.47
Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav (2009) 1.29
Medical marijuana: A panacea or scourge. Lung India (2014) 1.23
Medical marijuana: clearing away the smoke. Open Neurol J (2012) 1.21
Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther (2007) 1.17
The analgesic potential of cannabinoids. J Opioid Manag (2010) 1.16
Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol (2007) 1.12
Cannabis and the general practitioner--'going to pot'. Br J Gen Pract (2003) 1.08
Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag (2008) 1.05
Experience of pain among women with advanced HIV disease. AIDS Patient Care STDS (2009) 1.02
The pharmacotherapy of chronic pain: a review. Pain Res Manag (2006) 1.01
Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats. J Pharmacol Exp Ther (2012) 1.00
Prescribing cannabis: freedom, autonomy, and values. J Med Ethics (2004) 1.00
The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev (2011) 0.99
Cannabinoids for pain and nausea. BMJ (2001) 0.94
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) (2006) 0.93
Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) (2005) 0.93
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol (2006) 0.93
Monoacylglycerol lipase - a target for drug development? Br J Pharmacol (2012) 0.91
Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology (Berl) (2015) 0.91
Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury. Exp Neurol (2006) 0.90
Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol (2009) 0.88
Going beyond efficacy: strategies for cancer pain management. Curr Oncol (2008) 0.88
Combination Drug Therapy for Pain following Chronic Spinal Cord Injury. Pain Res Treat (2012) 0.87
[Cannabinoids--signal transduction and mode of action]. Schmerz (2005) 0.87
Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2. Oncotarget (2016) 0.87
Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.84
Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase. Bioorg Med Chem (2013) 0.84
New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag (2010) 0.84
Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. J Pain (2015) 0.83
The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J (2013) 0.81
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation. Curr Neuropharmacol (2016) 0.80
Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain. J Rehabil Res Dev (2009) 0.80
Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2. Int J Mol Sci (2014) 0.80
Medical marijuana programs - Why might they matter for public health and why should we better understand their impacts? Prev Med Rep (2015) 0.80
A user's guide to cannabinoid therapies in oncology. Curr Oncol (2016) 0.79
Cannabinoids for chronic pain. BMJ (2008) 0.79
Management of chronic pain in the rheumatic diseases with insights for the clinician. Ther Adv Musculoskelet Dis (2011) 0.78
Analgesia for patients with advanced disease: 2. Postgrad Med J (2004) 0.78
Cannabinoids in pain management. Cannabinoid receptor agonists will soon find their place in modern medicine. BMJ (2001) 0.77
Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers. Drugs R D (2016) 0.77
[Efficacy, tolerability, and safety of cannabinoids in gastroenterology : A systematic review]. Schmerz (2016) 0.76
An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease. J Pain (2016) 0.76
More evidence cannabis can help in neuropathic pain. CMAJ (2010) 0.76
Cannabinoids in pain management. Study was bound to conclude that cannabinoids had limited efficacy. BMJ (2001) 0.76
[Endogenous cannabinoid system. Effect on neuronal plasticity and pain memory]. Schmerz (2005) 0.76
[Pain therapy in addicted patients]. Schmerz (2006) 0.75
Review: cannabinoids and codeine have similar effects on pain relief, but cannabinoids commonly cause adverse psychotropic effects. ACP J Club (2002) 0.75
Cannabinoids in pain management. Spasticity is not the same as pain. BMJ (2001) 0.75
Cannabinoids in pain management. Few well controlled trials of cannabis exist for systemic review. BMJ (2001) 0.75
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. Parkinsons Dis (2016) 0.75
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet (1999) 37.76
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ (2001) 3.76
Developing a database of published reports of randomised clinical trials in pain research. Pain (1996) 2.40
Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia (1997) 1.77
Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav (1991) 1.51
The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther (1975) 1.49
Adverse effects of cannabis and cannabinoids. Br J Anaesth (1999) 1.49
Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol (1975) 1.42
Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain (1999) 1.36
Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med (1974) 1.34
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse (1987) 1.26
Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol (1982) 1.26
Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther (1994) 1.21
Nabilone in the treatment of multiple sclerosis. Lancet (1995) 1.19
Relief of pain by oral medications. A controlled evaluation of analgesic combinations. JAMA (1974) 1.12
Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther (1977) 1.02
Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther (1978) 1.00
Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol (1982) 0.99
Effects of moderate and high doses of marihuana on thermal pain: a sensory decision theory analysis. J Clin Pharmacol (1982) 0.98
Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther (1978) 0.96
Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci (1990) 0.95
Marijuana-produced changes in pain tolerance. Experienced and non-experienced subjects. Int Pharmacopsychiatry (1975) 0.93
Marihuana and pain. J Pharmacol Exp Ther (1974) 0.93
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Impact of covert duplicate publication on meta-analysis: a case study. BMJ (1997) 7.01
Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol (2001) 6.68
The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain (1997) 5.29
Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain (1998) 5.12
Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain (2000) 4.93
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Using numerical results from systematic reviews in clinical practice. Ann Intern Med (1997) 4.38
Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res (2000) 4.34
Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun (1995) 4.28
Role of toxigenic and invasive bacteria in acute diarrhea of childhood. N Engl J Med (1975) 4.23
Algorithm for neuropathic pain treatment: an evidence based proposal. Pain (2005) 3.92
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ (2001) 3.76
Examining the evidence in anesthesia literature: a critical appraisal of systematic reviews. Anesth Analg (2001) 3.48
Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer (2001) 3.40
Prevention of pain on injection with propofol: a quantitative systematic review. Anesth Analg (2000) 3.22
A systematic review of antidepressants in neuropathic pain. Pain (1996) 3.09
A high-yield strategy to identify randomized controlled trials for systematic reviews. Online J Curr Clin Trials (1993) 2.93
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology (1997) 2.93
Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ (1998) 2.89
Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob Agents Chemother (1986) 2.74
Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage (1999) 2.71
Searching the literature. Be systematic in your searching. BMJ (1993) 2.68
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ (2000) 2.68
Mre11 protein complex prevents double-strand break accumulation during chromosomal DNA replication. Mol Cell (2001) 2.65
Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg (2000) 2.63
Meta-analyses to evaluate analgesic interventions: a systematic qualitative review of their methodology. J Clin Epidemiol (1996) 2.47
ABC of monitoring drug therapy. Aminoglycoside antibiotics. BMJ (1992) 2.45
Amplified ribosomal DNA from Xenopus laevis has heterogeneous spacer lengths. Proc Natl Acad Sci U S A (1974) 2.42
Characterization of recombination intermediates from DNA injected into Xenopus laevis oocytes: evidence for a nonconservative mechanism of homologous recombination. Mol Cell Biol (1991) 2.40
Developing a database of published reports of randomised clinical trials in pain research. Pain (1996) 2.40
Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet (1992) 2.34
Rationing and the health authority. BMJ (1998) 2.34
Adjacent repeating units of Xenopus laevis 5S DNA can be heterogeneous in length. Cell (1976) 2.31
An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain (2000) 2.27
Systematic review of systematic reviews of acupuncture published 1996-2005. Clin Med (2006) 2.24
Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain. A quantitative systematic review. Acta Anaesthesiol Scand (2001) 2.18
BMA approves acupuncture. BMA report is wrong. BMJ (2000) 2.16
Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain (2000) 2.12
A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. BMJ (1997) 2.10
Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med (2001) 2.09
32-gauge spinal catheters through 26-gauge needles. Anaesthesia (1990) 2.05
Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth (2000) 2.04
Intravenous ketamine for CRPS: Making too much of too little? Pain (2010) 2.02
Mucins in the gastrointestinal tract in health and disease. Front Biosci (2001) 1.99
Degradation of linear DNA by a strand-specific exonuclease activity in Xenopus laevis oocytes. Mol Cell Biol (1989) 1.97
Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. Pain (1996) 1.97
Relative efficacy of oral analgesics after third molar extraction. Br Dent J (2004) 1.95
Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother (1986) 1.87
Involvement of single-stranded tails in homologous recombination of DNA injected into Xenopus laevis oocyte nuclei. Mol Cell Biol (1991) 1.87
Triglyceride fatty acids confirm a change in dietary fat. Clin Endocrinol (Oxf) (1977) 1.86
The Evolution and Involution of the Prostate Gland. Am J Pathol (1936) 1.84
Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1984) 1.81
Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain (2005) 1.79
Efficient homologous recombination of linear DNA substrates after injection into Xenopus laevis oocytes. Mol Cell Biol (1986) 1.77
Socioeconomic differentials in mortality: evidence from Glasgow graveyards. BMJ (1993) 1.76
Oral aspirin in postoperative pain: a quantitative systematic review. Pain (1999) 1.71
Anticonvulsant drugs for management of pain: a systematic review. BMJ (1995) 1.70
Intravenous regional sympathetic blockade for pain relief in reflex sympathetic dystrophy: a systematic review and a randomized, double-blind crossover study. J Pain Symptom Manage (1995) 1.69
Divergent functional properties of ryanodine receptor types 1 and 3 expressed in a myogenic cell line. Biophys J (2000) 1.69
Some patients don't need analgesics after surgery. J R Soc Med (1982) 1.68
Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J Chromatogr (1988) 1.67
Improved glucose control in maturity-onset diabetes treated with high-carbohydrate-modified fat diet. Br Med J (1979) 1.65
Systematic review of the use of honey as a wound dressing. BMC Complement Altern Med (2001) 1.63
Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol (1981) 1.62
Dysentery caused by Escherichia coli (S102-9) in calves: natural and experimental disease. Vet Pathol (1985) 1.60
The effects of physical activity and exercise training on psychological stress and well-being in an adolescent population. J Psychosom Res (1992) 1.59